Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Eardrum perforations and cholesteatoma linked to higher odds of dementia

13

Apr 2026

Eardrum perforations and cholesteatoma linked to higher odds of dementia

A new study published in Otolaryngology–Head and Neck Surgery, the official peer-reviewed publication of the American Academy of Otolaryngology–Head and Neck Surgery Foundation (AAO-HNSF), finds that two common and treatable causes of conductive hearing loss-eardrum perforations and cholesteatoma, a type of abnormal skin growth in the middle ear-are associated with higher odds of dementia.

Minimally-invasive stenting effectively treats painful post-thrombotic syndrome

13

Apr 2026

Minimally-invasive stenting effectively treats painful post-thrombotic syndrome

A major multi-site clinical trial co-led by researchers at Washington University School of Medicine in St. Louis has shown that post-thrombotic syndrome - a common and often painful complication suffered by many people who have experienced blockages of major veins due to blood clots - can be effectively treated with a minimally invasive procedure.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.